BridgeBio Pharma Inc
$ 77.70
-0.30%
15 Apr - close price
- Market Cap 15,107,734,000 USD
- Current Price $ 77.70
- High / Low $ 78.90 / 76.17
- Stock P/E N/A
- Book Value -10.71
- EPS -3.78
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.34 %
- ROE -17.90 %
- 52 Week High 84.94
- 52 Week Low 31.77
About
BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. The company is headquartered in Palo Alto, California.
Analyst Target Price
$100.61
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-10-29 | 2025-08-05 | 2025-04-30 | 2025-02-20 | 2024-11-01 | 2024-08-01 | 2024-05-02 | 2024-02-22 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | -0.9389 | -0.95 | -0.95 | -0.9888 | -1.3744 | -0.8596 | -0.39 | -0.2 | -0.96 | -1.08 | -0.98 | -0.92 |
| Estimated EPS | -0.716 | -0.88 | -0.75 | -0.89 | -1.09 | -0.98 | -1.06 | -0.71 | -0.91 | -0.82 | -0.83 | -0.83 |
| Surprise | -0.2229 | -0.07 | -0.2 | -0.0988 | -0.2844 | 0.1204 | 0.67 | 0.51 | -0.05 | -0.26 | -0.15 | -0.09 |
| Surprise Percentage | -31.1313% | -7.9545% | -26.6667% | -11.1011% | -26.0917% | 12.2857% | 63.2075% | 71.831% | -5.4945% | -31.7073% | -18.0723% | -10.8434% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.7 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BBIO
2026-04-14 03:38:48
An officer at BridgeBio Pharma (BBIO.US) sold 225,000 shares of common stock for a total value of $5.97 million. The transaction was executed at an average price of $26.51 per share. This sale indicates a significant executive divestment in the company's stock.
2026-04-14 00:39:46
BridgeBio Pharma CEO Neil Kumar sold approximately $5.9 million worth of BBIO stock through pre-arranged trading plans on April 9 and 10, 2026. These sales were executed through trusts where Kumar serves as co-trustee, with the stock price climbing after the transactions. Despite the sales, Kumar retains a significant stake in the company, which continues to show strong progress with positive analyst ratings and significant clinical and regulatory developments.
2026-04-14 00:38:48
BridgeBio Pharma CEO Neil Kumar sold 40,000 shares of the company's stock for $2.98 million on April 9th, 2026, under a pre-arranged trading plan. This transaction represents a 6.10% decrease in his holdings and marks the fourth large sale in the past year, which investors are watching closely for signals about the company's future direction. Kumar still directly owns over 615,000 shares valued at approximately $45.9 million.
2026-04-13 22:10:06
Entities linked to BridgeBio Pharma, Inc. CEO Neil Kumar, specifically family trusts where he serves as co-trustee, sold 80,000 shares of BBIO common stock on April 9-10, 2026. The sales, executed under a pre-arranged Rule 10b5-1 plan adopted in March 2025, were conducted at prices in the mid-$70s per share. Despite these transactions, the trusts and Kumar's direct holdings still retain several million shares of BBIO.
2026-04-13 22:10:06
BridgeBio Pharma CEO Neil Kumar sold approximately $5.9 million worth of BBIO stock on April 9 and 10, 2026, through pre-arranged trading plans. Despite these sales, conducted indirectly via trusts, Kumar maintains significant holdings. The company has seen a 130% stock gain and received positive analyst ratings and recent news, including a New Drug Application submission and sustained clinical benefits for its drug acoramidis.
2026-04-13 08:10:06
BridgeBio Pharma (BBIO) has gained investor attention following positive data for its ATTR-CM drug acoramidis and an FDA New Drug Application for BBP-418. While its share price has eased from recent highs, its long-term performance remains strong. Valuation narratives suggest BBIO is undervalued at $100.05, but a high P/S ratio indicates potential risks, highlighting mixed sentiment on its future growth and profitability.
